“Innovations in medical technologies deliver better healthcare and cost savings. These benefits are threatened by knee-jerk reactions to the extremely rare ‘bad apples’ – the PIP breast implants or the metal-on-metal hip replacements. CASMI has an important role to play in speaking up for medical technologies so that the regulatory landscape may be made fit-for-purpose, and never stand in the way of much-needed patient benefit.
Quentin Pankhurst is the Director of the Institute of Biomedical Engineering at University College London. The objective of the IBME is to bring together UCL’s excellence in academic and clinical R&D – around a thousand staff, fellows, nurses and students in 35 different centres, departments and institutes – to create the world’s best research centre for biomedical engineering. The IBME’s goal is to be the world’s fastest and most cost-effective deliverer of patient benefit by harnessing the power of university-based innovation and experimental medicine in the UK.
He is also the Director of the Davy-Faraday Research Laboratory and Wolfson Professor of Natural Philosophy – a post once held by Lord Ernest Rutherford – at the Royal Institution of Great Britain, in London. Here he runs research programmes in bio- and nanomagnetism aimed at making practical advances in the use of magnetic nanoparticles in healthcare. These include medical imaging devices, targeted regenerative medicine, molecular imaging microscopy for living cells, and the development of multi-functional nanoparticles for therapy and diagnostics.
He is a founder and CTO of Endomagnetics Ltd, a spin-out company which is commercialising the SentiMag™, an intra-operative device for breast cancer surgery.